Affimed is seeking fundsWhile German Nasdaq company Affimed (AFMD) had an accumulated loss of over €100m, an annual development cost of about €38m for its Tandab pipeline, and an income of only about €8m from collaborations … more ➔
Octimet bags €11m for development of can... Belgian start-up company Octimet Oncology NV has secured €11.3m in a series A financing round. The funds will be used to develop two MET kinase blockers to treat solid tumours. more ➔
Joint-venture Fibrocor tackles fibrosis Drug screening expert Evotec AG and Ontario-based MaRS Innovation have launched the joint venture company Fibrocor Therapeutics LP to tackle fibrosis, an unmet medical need and multi-billion US dollars … more ➔
New technology speeds up mapping of DNA-pr...Scientists at EPFL have developed a technique that can be a game-changer for genetics by making the characterisation of DNA-binding proteins much faster, more accurate, and efficient. more ➔
Telix licenses Wilex’ girentuximab p... German Wilex has licensed its clear cell renal cell carcinoma (ccRCC) antibody Redectane to Australian biopharma company Telix Pharmaceuticals. Redectane is a radiolabeled version of Wilex’ Phase III … more ➔
EU neonicotinoid ban causes environmental...Severe economic and environmental damage: A study commissioned by EU industry association Euroseeds says that the ban of a certain class of insecticides to protect bees causes a lot of ecologic and economic … more ➔
Curevac reports another failed cancer vacc... For thirty years, industry has worked hard to establish vaccines that can cure cancer. At the 35th JP Morgan Healthcare Conference, German Curevac reported another failure. It remains open whether cancer … more ➔
Researchers overcome chemotherapy resistan... German researchers have found a biomarker that reliably predicts outcomes of blood cancer treatment with the chemotherapeutic cytarabine. Targeting the biomarker restored cytarabine sensitivity. more ➔
Caution returns to European biotech stocksAfter the record-breaking year of 2015, biotech stock markets exercised more caution in 2016. However, according to a new report, this represents a healthy reset rather than a new crisis. more ➔
Roche gets FDA priority review for atezoli...Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, … more ➔
